Nama's AI scorecard currently rates Sarepta Therapeutics Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SRPT's P/E ratio?

Sarepta Therapeutics trades at a trailing price-to-earnings ratio of 50.9.

When does SRPT report earnings?

Sarepta Therapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.10.

What is the SRPT price target?

The median analyst price target from 22 analysts is $20.00, with a range of $5.00 – $38.00.

Is SRPT Shariah compliant?

Nama's AAOIFI-style screen reads Sarepta Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Sarepta Therapeutics (SRPT)

Healthcare · Biotechnology · NASDAQ

Sarepta Therapeutics (SRPT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.88B, a trailing price-to-earnings ratio of 50.9 and a free-cash-flow yield of -17.7%. Over the most recent reported fiscal year, revenue grew 15.6%. Nama's AI scorecard rates it Sell, 3.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.9/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -0.8% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-89.7%

How far the last close sits under the highest price of the past five years.

Market cap	$1.88B
Trailing P/E	50.9
Price / book	1.2
Price / sales	0.9
FCF yield	-17.7%
Dividend yield	—
Gross margin	59.1%
Operating margin	-3.1%
Net margin	-6.9%
Revenue growth (YoY)	+15.6%
Revenue growth (3-yr annual)	+33.1%
EPS growth (YoY)	-238.5%
FCF/share growth (YoY)	—
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

SRPT earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.10). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.13	$0.36	-63.9%	—
Q2 2026	Aug 5, 2026	$0.64	$0.49	+30.6%	$401.25M
Q1 2026	May 6, 2026	$3.16	$1.05	+200.9%	$730.80M
Q4 2025	Feb 25, 2026	-$3.58	-$0.77	-364.9%	$442.93M

SRPT analyst price target

Median target $20.00 from 22 analysts, ranging $5.00 – $38.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live SRPT data on Nama Insights →

Recent Congressional trades

Sarepta Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	May 6, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023

SRPT FAQ

Is SRPT a buy?: Nama's AI scorecard currently rates Sarepta Therapeutics Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SRPT's P/E ratio?: Sarepta Therapeutics trades at a trailing price-to-earnings ratio of 50.9.
When does SRPT report earnings?: Sarepta Therapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.10.
What is the SRPT price target?: The median analyst price target from 22 analysts is $20.00, with a range of $5.00 – $38.00.
Is SRPT Shariah compliant?: Nama's AAOIFI-style screen reads Sarepta Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.